Trisalus Life Sciences, Inc. (TLSIW) — SEC Filings
Trisalus Life Sciences, Inc. (TLSIW) — 43 SEC filings. Latest: 10-Q (Nov 13, 2025). Includes 29 8-K, 6 10-Q, 2 DEF 14A.
View Trisalus Life Sciences, Inc. on SEC EDGAR
Overview
Trisalus Life Sciences, Inc. (TLSIW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 13, 2025: TriSalus Life Sciences, Inc. (TLSIW) reported a significant increase in revenue for the nine months ended September 30, 2025, reaching $31.946 million, up from $21.170 million in the prior year, representing a 50.9% increase. Despite this revenue growth, the company experienced a substantial net los
Sentiment Summary
Across 43 filings, the sentiment breakdown is: 2 bearish, 40 neutral, 1 mixed. The dominant filing sentiment for Trisalus Life Sciences, Inc. is neutral.
Filing Type Overview
Trisalus Life Sciences, Inc. (TLSIW) has filed 6 10-Q, 29 8-K, 1 10-K/A, 2 DEF 14A, 2 10-K, 2 SC 13G, 1 S-1 with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (43)
Risk Profile
Risk Assessment: Of TLSIW's 38 recent filings, 3 were flagged as high-risk, 20 as medium-risk, and 15 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $31.946M |
| Net Income | $(29.474)M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $22.687M |
| Operating Margin | N/A |
| Total Assets | $36.463M |
| Total Debt | $32.764M |
Key Executives
- Dr. David L. Smith
- Ms. Jennifer L. Smith
- Ms. Jennifer L. Johnson
- Dr. Michael J. McGarrity
- Dr. David M. Rind
- Dr. Robert L. T. Ryan
- David M. Johnson
- Dr. Michael J. McGarry
- Dr. David L. R. Smith
- Ms. Jennifer L. Jones
Industry Context
TriSalus Life Sciences operates in the life sciences sector, which is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. The industry is competitive, with companies often seeking strategic partnerships or financing to fund growth and innovation. Trends include advancements in medical technology and increasing demand for specialized healthcare solutions.
Top Tags
financial-reporting (7) · 8-K (6) · corporate-action (4) · filing (4) · 10-Q (4) · management-change (4) · board-appointment (4) · medical-devices (4) · Medical Devices (3) · governance (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenue | $31.946M | Increased by 50.9% for the nine months ended September 30, 2025, from $21.170 million in 2024. |
| Net Loss | $(29.474)M | Widened from $(19.937) million in the prior nine-month period. |
| Net Loss Attributable to Common Stockholders | $(59.937)M | Significantly increased from $(22.342) million in 2024, impacted by preferred stock conversion. |
| Cash and Cash Equivalents | $22.687M | Increased from $8.525 million at December 31, 2024. |
| Net Cash Provided by Financing Activities | $30.487M | Primarily from common stock and debt issuance, funding operations. |
| Common Shares Outstanding | 49,964,311 | As of November 10, 2025, indicating potential dilution. |
| Series A Preferred Stock Conversion Inducement | $(18.516)M | A significant non-cash charge impacting net loss attributable to common stockholders. |
| Proceeds from Issuance of Debt | $10.000M | New debt taken on during the nine months ended September 30, 2025. |
| SEC File Number | 001-39813 | Identifies the company's filings with the SEC. |
| EIN | 853009869 | Employer Identification Number for tax purposes. |
| Q2 2025 Revenue | $11.213M | Increased 52.2% from $7.364M in Q2 2024 |
| H1 2025 Revenue | $20.380M | Increased 47.5% from $13.821M in H1 2024 |
| Q2 2025 Net Loss | $(8.288M) | Increased from $(4.332M) in Q2 2024 |
| H1 2025 Net Loss | $(18.663M) | Increased from $(17.538M) in H1 2024 |
| Accumulated Deficit | $298.2M | As of June 30, 2025, indicating significant historical losses |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Trisalus Life Sciences, Inc. (TLSIW)?
Trisalus Life Sciences, Inc. has 43 recent SEC filings from Jan 2024 to Nov 2025, including 29 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of TLSIW filings?
Across 43 filings, the sentiment breakdown is: 2 bearish, 40 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Trisalus Life Sciences, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Trisalus Life Sciences, Inc. (TLSIW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Trisalus Life Sciences, Inc.?
Key financial highlights from Trisalus Life Sciences, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for TLSIW?
The investment thesis for TLSIW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Trisalus Life Sciences, Inc.?
Key executives identified across Trisalus Life Sciences, Inc.'s filings include Dr. David L. Smith, Ms. Jennifer L. Smith, Ms. Jennifer L. Johnson, Dr. Michael J. McGarrity, Dr. David M. Rind and 5 others.
What are the main risk factors for Trisalus Life Sciences, Inc. stock?
Of TLSIW's 38 assessed filings, 3 were flagged high-risk, 20 medium-risk, and 15 low-risk.
What are recent predictions and forward guidance from Trisalus Life Sciences, Inc.?
Forward guidance and predictions for Trisalus Life Sciences, Inc. are extracted from SEC filings as they are enriched.